Over the past 35 years, my research work has been focusing on addressing a question of how thrombus is formed and elucidating the distinct mechanisms between thrombosis and hemostasis, at Japanese pharmaceutical company and academia (The Scripps Research Institute, USA).

It has been known that thrombus formation has a crucial role as a host-defense system in sustaining our life, excessive thrombus formation may cause life-treating diseases. Such diseases include heart attack, stroke, and deep vein thrombosis (DVT) which are closely associated with serious natural disasters such as earthquake. To date, many pioneer researchers have elucidated the mechanisms of thrombus formation: These include adhesion and activation of platelets, blood coagulation cascade reactions, and fibrinolytic system.

Despite advancing our knowledge on thrombus formation and providing patients with anti-thrombotic drugs with higher safety, the number of patients with thromboembolic diseases remains elevated. Therefore, preventing thrombotic diseases is sought as top priority to reduce the number of deceased patients and improve a quality life of patients with risks of thrombosis.

Our goal is to reduce the number of patients suffering from thrombus-related diseases by 80% and to contribute to realization of society overcoming thrombotic diseases. Our hometown Kumamoto was hit by one of the worst earthquakes in 2016 and many precious lives were lost. In the disaster we had seen many people were suffering from disaster-associated thrombosis including DVT while staying in community centers and other facilities used as evacuation shelters.

In 2019, We founded our company in Kumamoto city in the process of earthquake recovery and had the opportunity to translate our technology. To achieve our goals, we will be continuing not only to advance our understanding of thrombosis, hemostasis, and vascular biology, but also to translate our breakthrough research findings to prognostic and diagnostic systems for unmet needs.

I sincerely appreciate your support.

Yuichi Kamikubo, Ph.D.
President and CEO